MPNs

A novel blood based surveillance test using artificial intelligence and next-generation sequencing identified relapse a median of 41 days before clinical detection in patients with AML or MDS following transplant.

New research defines distinct therapeutic strategies for the 2 classes of CALR mutations in myelofibrosis, with implications for future patient management and clinical trial design.

Post hoc data suggest Orca-T may boost survival and cut non-relapse mortality after allogeneic stem cell transplant in MDS and leukemias, pending phase 3 validation.

During a live event, Edward Pearson, MD, and participants discussed their approaches to using JAK inhibitors in myelofibrosis based on blood cell counts.

Phase 2 trial tests azacitidine plus venetoclax in therapy-related high-risk MDS, showing remissions and better posttransplant survival despite TP53 mutations.

Explore the evolving landscape of myelodysplastic syndromes management, highlighting personalized therapies and novel treatment strategies for better patient outcomes.

FDA designates OPN-2853 as an orphan drug for myelofibrosis, showing promising results in spleen size reduction and safety in clinical trials.

The FDA reviews ropeginterferon alfa-2b-njft for essential thrombocythemia, showing promising efficacy in clinical trials for patients.

CK0804, a novel Treg therapy, gains FDA orphan drug status for myelofibrosis, promising new hope for patients with limited treatment options.

A new drug application for rusfertide aims to transform polycythemia vera treatment, reducing phlebotomy needs and improving patient outcomes.

Roxadustat receives orphan drug designation for myelodysplastic syndromes, highlighting its potential to improve transfusion independence in patients.

The MANIFEST-2 trial reveals that pelabresib combined with ruxolitinib significantly improves outcomes for myelofibrosis patients compared to standard treatments.

New trials reveal INCA033989 shows promise for treating CALR exon 9-mutated myelofibrosis, demonstrating efficacy and tolerability in patients.

Rusfertide shows sustained hematocrit control and high phlebotomy ineligibility in polycythemia vera patients, demonstrating safety and efficacy through 52 weeks.

CLN-049 gains FDA fast track designation, offering hope for patients with relapsed/refractory AML through innovative immunotherapy solutions.

New trial results reveal ropeginterferon alfa-2b's effectiveness for essential thrombocythemia, offering hope for patients resistant to standard treatments.

Olutasidenib shows promising long-term efficacy and safety in treating relapsed or refractory mutant IDH1 acute myeloid leukemia, enhancing patient outcomes.

The FDA designates M2T-CD33 as an orphan drug, highlighting its potential as a safer, innovative treatment for acute myeloid leukemia.

Bexmarilimab combined with azacitidine shows promising efficacy and safety in patients with high-risk myelodysplastic syndrome, paving the way for new treatment options.

Novel approaches in MDS focus on HMA doublets, but transplant remains the only curative option to date.

A phase 1 trial shows IO-202 combined with azacitidine effectively treats relapsed/refractory monocytic leukemias, demonstrating promising response rates.

A recent trial shows omacetaxine and venetoclax combination benefits patients with MDS but not AML, highlighting the need for further research.

A clinical trial reveals no survival benefit from stem cell transplantation in lower-risk MDS patients, highlighting the need for improved posttransplant outcomes.